ArticleBMC neurology2023
Remote at-home wearable-based gait assessments in Progressive Supranuclear Palsy compared to Parkinson's Disease.
Article in BMC neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Remote Monitoring in Progressive Supranuclear Palsy, an Alzheimer's Disease Related Dementia
Digital Health Technologies For Monitoring Disease Symptoms in Progressive Supranuclear Palsy and Dementia With Lewy Bodies
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.
- Wearable Devices for Remote Monitoring of Chronic Diseases: Systematic Review.JMIR mHealth and uHealth · 2026Pooled it
- Concurrent Validity and Between-System Agreement of a Commercial Wearable Inertial Sensor System for Gait and Postural Sway Assessment in Progressive Supranuclear Palsy.Sensors (Basel, Switzerland) · 2026Article
- Wearables for Telemonitoring in ATTR-Amyloidosis: Current Perspectives.Sensors (Basel, Switzerland) · 2026Review
- From clinical phenotypes to molecular precision: multimodal biomarkers for progressive supranuclear palsy.Frontiers in neuroscience · 2026Review
- Pathway to Regulatory Approval of Digital Health Technologies in Progressive Supranuclear Palsy: A Scoping Review.Brain sciences · 2025Review
- Applying Wearable Sensors and Machine Learning to the Diagnostic Challenge of Distinguishing Parkinson's Disease from Other Forms of Parkinsonism.Biomedicines · 2025Article
- Using wearable sensors and machine learning to assess upper limb function in Huntington's disease.Communications medicine · 2025Article
- Association between Physical Function at Discharge and Fall Frequency One Month after Discharge in Patients with Progressive Supranuclear Palsy.Physical therapy research · 2025Article
- Using Wearable Sensors and Machine Learning to Assess Upper Limb Function in Huntington's Disease.Research square · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundWearable sensors can differentiate Progressive Supranuclear Palsy (PSP) from Parkinson's Disease (PD) in laboratory settings but have not been tested in remote settings.
objectivesTo compare gait and balance in PSP and PD remotely using wearable-based assessments.
methodsParticipants with probable PSP or probable/clinically established PD with reliable caregivers, still able to ambulate 10 feet unassisted, were recruited, enrolled, and consented remotely and instructed by video conference to operate a study-specific tablet solution (BioDigit Home ™) and to wear three inertial sensors (LEGSys™, BioSensics LLC, Newton, MA USA) while performing the Timed Up and Go, 5 × sit-to-stand, and 2-min walk tests. PSPRS and MDS-UPDRS scores were collected virtually or during routine clinical visits.
resultsBetween November, 2021- November, 2022, 27 participants were screened of whom 3 were excluded because of technological difficulties. Eleven PSP and 12 PD participants enrolled, of whom 10 from each group had complete analyzable data. Demographics were well-matched (PSP mean age = 67.6 ± 1.3 years, 40% female; PD mean age = 70.3 ± 1.8 years, 40% female) while disease duration was significantly shorter in PSP (PSP 14 ± 3.5 months vs PD 87.9 ± 16.9 months). Gait parameters showed significant group differences with effect sizes ranging from d = 1.0 to 2.27. Gait speed was significantly slower in PSP: 0.45 ± 0.06 m/s vs. 0.79 ± 0.06 m/s in PD (d = 1.78, p < 0.001).
conclusionOur study demonstrates the feasibility of measuring gait in PSP and PD remotely using wearable sensors. The study provides insight into digital biomarkers for both neurodegenerative diseases.
trial registrationClinicalTrials.gov Identifier: NCT04753320, first posted Febuary 15, 2021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.